About Broad Street Alerts:
Big opportunities in Small Cap’s
Broadstreetalerts.com recent profiles and track record, 157% in verifiable potential gains for our members in December 2015 alone.
December 29th, 2015- (NASDAQ: INVT) opened $1.35/share hit a high midday of $2.82/share over 100% in gains for our members.
December 15th, 2015-(NYSE-MKT: XXII) opened at $1.29 hit a high of $1.54 within 3 days for gains of 19% for our members.
December 2nd, 2015- (NASDAQ: TCCO) opened at $3.25 hit a high of $4.50 within 3 days for 38% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business. We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Due Diligence Report: 73% Run Up in the Last Month Has No Resistance Ahead
Summary:
CymaBay Therapeutics Inc., incorporated on October 5, 1988, is a biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan disorders. Arhalofenate, the Company’s lead product candidate, is used to treat gout. The Company has completed five Phase II clinical trials of Arhalofenate in patients with gout. The Company’s second product candidate, MBX-8025, is used to treat disorder linked to deficits in lipid storage, handling and utilization, many of which result in metabolic disorders. The Company has completed five Phase I and one Phase II clinical trials of MBX-8025. The Company’s MBX-2982 is a treatment for type 2 diabetes that targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. MBX-2982 has completed four Phase I studies and one Phase II study.
Arhalofenate is an anti-inflammatory uricosuric drug that reduces the risk of gout flares while also lowering sUA (serum uric acid). The arhalofenate portfolio consists of approximately 135 issued patents and 87 pending patent applications relating to composition, method of use or methods of manufacture.
MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). An agonist is a substance that elicits a response by binding to a receptor. The PPARd receptor is a nuclear receptor that regulates genes involved in lipid storage, transport and metabolism (particularly fatty acid oxidation) and in insulin signaling and sensitivity. MBX-8025 is also used to treat a variety of disorders of lipid metabolism and certain diseases of the liver. The MBX-8025 portfolio consists of approximately 273 issued patents and 81 pending patent applications related to composition and method of use.
MBX-2982 is an oral, G-protein coupled receptor (GPR119) agonist being evaluated as a therapeutic agent for patients with T2DM (Type 2 diabetes), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as beneficial effects on islet health. Type 2 diabetes (T2DM) is a chronic debilitating disease characterized by a progressive loss of the normal control of glucose levels in the blood and other tissues.
CymaBay Therapeutics Inc. has a current market capitalization of $69.92 with 23.45 M outstanding shares. Its daily average volume traded is 0.48 M shares.
Financial Highlights (Q4 2015):
Revenue: Nil
Gross Profit: nil
Net Income: -5.98 M
Cash and Cash Equivalents: 41.48 M
Total Debt: 9.31 M
Recent News and Analysis:
The company recently provided corporate highlights and announced financial results for the quarter and year ended December 31, 2015. “We have made significant progress during the last quarter in advancing the development of our two key clinical assets,” said Harold Van Wart, President and Chief Executive Officer of CymaBay. “Earlier in March, we reported some encouraging top-line data from our pilot Phase 2 study in patients with homozygous familial hypercholesterolemia. Analysis of the data showed that MBX-8025 demonstrated the ability to lower LDL-Cholesterol in a majority of patients, despite raising PCSK9 levels. We are evaluating the feasibility of conducting a second pilot study in combination with a PCSK9 inhibitor to assess whether the reductions in LDL-C can be amplified by neutralizing PCSK9.” “Last quarter, we also initiated a 12 week, placebo-controlled, dose ranging Phase 2 study of MBX-8025 in 75 patients with primary biliary cholangitis,” said Dr. Van Wart. “We have consistently observed reductions in markers of cholestasis in clinical studies in other populations that we hope will be replicated in this study.” “For arhalofenate, our drug candidate for the treatment of gout, we have completed our End-of-Phase 2 discussions with the FDA and now have clear direction as to how to conduct a Phase 3 program that could capture the dual benefits of arhalofenate,” continued Dr. Van Wart. “Our goal is to sign one or more partnerships in order to initiate the Phase 3 program before the end of 2016.”
In March 2016, CymaBay announced results from a pilot Phase 2 clinical study that demonstrated efficacy of MBX-8025 in patients with homozygous familial hypercholesterolemia (HoFH, an autosomal genetic disease characterized by loss-of-function mutations in both alleles of the LDL receptor gene. The results showed that MBX-8025 provided a clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) for a subset of patients. A responder analysis showed that 7 subjects (or 58%) exhibited a greater than or equal to 15% decrease in LDL-C, including one patient that was LDL receptor negative. The overall mean change in LDL-C for all subjects was a decrease of 10%. Eight subjects exhibited a decrease in LDL-C with a group mean of 16%, including 3 that showed a greater than or equal to 20% decrease. Mean PCSK9 levels, associated with causing LDL-C to rise, increased significantly during treatment by a mean of 43%. CymaBay is now evaluating the feasibility of conducting a second pilot Phase 2 clinical study to further understand the potential benefits of MBX-8025 in patients with HoFH that are currently being treated with a PCSK9 inhibitor. The Food and Drug Administration (FDA) granted CymaBay orphan drug designation for MBX-8025 to treat HoFH and severe hypertriglyceridemia in 2015.
Conclusions:
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a one year price target of $5.00 on the stock, this valuation is based on 2 number of opinions. This consensus target price comprises projections from analysts polled by First Call. In order to get a glimpse of Wall Street sentiment, we can look to brokerage analyst estimates. On a one to five ratings scale where 1 refers to a Strong Buy, 2 directs a Buy, 3 a Hold, 4 indicates a Sell and 5 a Strong Sell. CymaBay Therapeutics Inc. (NASDAQ: CBAY) currently has an average brokerage recommendation of 1.00 according to analysts. This is the average number based on the total brokerage firms taken into consideration by Zacks investment research.
Sources:
- http://www.reuters.com/finance/stocks/companyProfile?rpc=66&symbol=CBAY.O
- https://www.google.ca/finance?q=cbay&hl=en&gl=ca&ei=5uEXV6i5LoSvjAHq3rlY
- http://finance.yahoo.com/q?s=CBAY&ql=0
- http://finance.yahoo.com/news/cymabay-reports-fourth-quarter-full-200500749.html
- http://www.thepointreview.com/notable-mover-cymabay-therapeutics-inc-nasdaqcbay/
Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it, and I have no business relationship with any company whose stock is mentioned in the article. I reserve the right to sell the redistribution rights to this report for up to two hundred fifty dollars/news source.
The information contained herein is not intended to be investment advice and does not constitute any form of invitation or inducement by Robert Borowski, MSc. to engage in investment activity. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security. Securities, financial instruments, strategies, or commentary mentioned herein may not be suitable for all investors and this material is not intended for any specific investor and does not take into account an investor’s particular investment objectives, financial situations or needs. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only current as of the stated date of their issue. Prices, values, or income from any securities or investments mentioned in this report may fluctuate, and an investor may, upon selling an investment lose a portion of, or the entire principal amount invested. Past performance is no guarantee of future results. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.
DISCLAIMER
Broad Street Alerts has compensated the author of this report up to two hundred and fifty dollars for the redistribution rights for a period of up to 30 days.
BroadStreetAlerts.com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We have not been compensated in any form by any entity for this report on CBAY and we do not own any positions. SCS LLC has been compensated up to twenty thousand dollars for the mention of INVT and XXII by star media LLC however, those contracts have expired. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.